EP1450816A4 - METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE - Google Patents

METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE

Info

Publication number
EP1450816A4
EP1450816A4 EP02802882A EP02802882A EP1450816A4 EP 1450816 A4 EP1450816 A4 EP 1450816A4 EP 02802882 A EP02802882 A EP 02802882A EP 02802882 A EP02802882 A EP 02802882A EP 1450816 A4 EP1450816 A4 EP 1450816A4
Authority
EP
European Patent Office
Prior art keywords
cholesterite
concentration
increased
connection
treating disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02802882A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1450816A2 (en
Inventor
Shutsung Liao
Ching Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of EP1450816A2 publication Critical patent/EP1450816A2/en
Publication of EP1450816A4 publication Critical patent/EP1450816A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP02802882A 2001-11-08 2002-11-08 METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE Withdrawn EP1450816A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
US348020P 2001-11-08
PCT/US2002/035900 WO2003039480A2 (en) 2001-11-08 2002-11-08 Method of treating disorder related to high cholesterol concentration

Publications (2)

Publication Number Publication Date
EP1450816A2 EP1450816A2 (en) 2004-09-01
EP1450816A4 true EP1450816A4 (en) 2008-02-13

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02802882A Withdrawn EP1450816A4 (en) 2001-11-08 2002-11-08 METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE

Country Status (5)

Country Link
EP (1) EP1450816A4 (enExample)
JP (1) JP2005508368A (enExample)
CA (1) CA2466033A1 (enExample)
TW (1) TW200300078A (enExample)
WO (1) WO2003039480A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
CA2585623C (en) 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
CA2668661A1 (en) 2006-11-13 2008-05-29 Novartis Ag Substituted pyrazole and triazole compounds as ksp inhibitors
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
MX2015012437A (es) * 2013-03-13 2016-04-15 Sage Therapeutics Inc Esteroides neuroactivos, composiciones, y usos de los mismos.
JP2016193835A (ja) * 2013-09-04 2016-11-17 学校法人常翔学園 核内受容体肝臓ｘ受容体アゴニスト
TWI734665B (zh) 2013-12-24 2021-08-01 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2991214C (en) 2015-07-06 2024-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11117924B2 (en) 2015-07-06 2021-09-14 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
MA44526A (fr) 2016-04-01 2021-06-02 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
TWI815796B (zh) 2016-08-02 2023-09-21 美商杜瑞克公司 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
US11111266B2 (en) 2016-10-18 2021-09-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405818A (en) * 1972-12-06 1975-09-10 Shionogi & Co 6beta-amino-steroids and the preparation thereof
WO1994002503A1 (en) * 1992-07-22 1994-02-03 Enosys S.A. Bile acid derivative and use thereof in therapy
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1405818A (en) * 1972-12-06 1975-09-10 Shionogi & Co 6beta-amino-steroids and the preparation thereof
WO1994002503A1 (en) * 1992-07-22 1994-02-03 Enosys S.A. Bile acid derivative and use thereof in therapy
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LAFFITTE B A ET AL: "LXRS CONTROL LIPID-INDUCIBLE EXPRESSION OF THE APOLIPOPROTEIN E GENE IN MACROPHAGES AND ADIPOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 2, 16 January 2001 (2001-01-16), pages 507 - 512, XP001097136, ISSN: 0027-8424 *
SONG C ET AL: "EFFECTS OF SELECTIVE LIVER X RECEPTOR AGONIST ON ATHEROSCLEROSIS PROGRESSION AND REGRESSION OF APOE KNOCK-OUT MICE", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 104, no. 17, 23 October 2001 (2001-10-23), pages II329, XP009016063, ISSN: 0009-7322 *
SONG C ET AL: "Hypolipidemic effects of selective liver X receptor alpha agonists", STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 66, no. 9, September 2001 (2001-09-01), pages 673 - 681, XP004304415, ISSN: 0039-128X *
SONG C ET AL: "SELECTIVE ACTIVATION OF LIVER X RECEPTOR ALPHA BY 6ALPHA-HYDROXY BILE ACIDS AND ANALOGS", STEROIDS, ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, US, vol. 65, no. 8, 2000, pages 423 - 427, XP000952749, ISSN: 0039-128X *
SPARKS D L ET AL: "Link between heart disease, cholesterol, and Alzheimer's disease: a review.", MICROSCOPY RESEARCH AND TECHNIQUE 15 AUG 2000, vol. 50, no. 4, 15 August 2000 (2000-08-15), pages 287 - 290, XP002462914, ISSN: 1059-910X *

Also Published As

Publication number Publication date
EP1450816A2 (en) 2004-09-01
JP2005508368A (ja) 2005-03-31
TW200300078A (en) 2003-05-16
WO2003039480A2 (en) 2003-05-15
WO2003039480A3 (en) 2003-06-19
CA2466033A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
EP1450816A4 (en) METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE
DE60215241D1 (de) Verfahren und Vorrichtung zur Reduzierung von Störungen in dekodierten Bildern mit Nachfilterung
DE60120520D1 (de) Verfahren zur behandlung von abwasser
DE60122532D1 (de) Verfahren zur behandlung von mehreren bohrlochintervallen
DE60233415D1 (de) Vorrichtung und verfahren zur herstellung von mit kohlensäure versetztem quellwasser und von kohlensäurehaltigem wasser
DE60103174D1 (de) Verfahren zur verhinderung oder verminderung der trübung in getränken
DE69903332D1 (de) Verfahren zur abreicherung der metallionenkonzentration in salzlösungen
EP1589990A4 (en) METHOD OF TREATING CANCER IN HUMANS
DE60106854D1 (de) Verfahren und Vorrichtung zur Elektroentionisierung von Wasser
DE60206052D1 (de) System und verfahren zur bearbeitung von flugplandaten
DE60102016D1 (de) Verfahren zur behandlung von beweggungsstörungen
DE60017188D1 (de) Verfahren zur umsetzung von synthesegas in höheren kohlenwasserstoffen
DE60210199D1 (de) Verfahren zur Bestimmung von Typgruppen in Bildern
DE60104188D1 (de) Verfahren und vorrichtung zur behandlung von wasser/abwasser
DE60104156D1 (de) Vorrichtung und Verfahren zur Reinigung von Wasser
ATE296915T1 (de) Verfahren zur textilbehandlung
DE60304649D1 (de) Verfahren und Vorrichtung zur Reduktion von falschen Konturen in Digitalanzeigen mit Pulszahlmodulation
DE60302319D1 (de) System und Verfahren zur Reinigung von Wasser
DE69915390D1 (de) Vorrichtung und verfahren zur ultraviolett-behandlung von fluiden
DE69907349D1 (de) Verfahren zur Verminderung von Stress in GaN Bauelementen
DE69919421D1 (de) Verfahren und Vorrichtung zur Behandlung von Lebensmitteln mit Ozon
EP1635801A4 (en) METHODS OF TREATMENT AND PREVENTION OF CARDIAC ARRHYTHMIA
EP1200538A4 (en) PROCESS FOR TREATING OIL ACIDS
ATE374799T1 (de) Verfahren zur behandlung von pigmenten in partikulärer form
DE60107351D1 (de) Verfahren zur Zuführung von Reagenz

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SONG, CHING

Inventor name: LIAO, SHUTSUNG

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20071219BHEP

Ipc: A61P 9/10 20060101ALI20071219BHEP

Ipc: A61P 3/06 20060101ALI20071219BHEP

Ipc: A61K 31/575 20060101AFI20071219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080114

17Q First examination report despatched

Effective date: 20090206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090818